TrialThe lancet. HIV2024

Safety and immunogenicity of a polyvalent DNA-protein HIV vaccine with matched Env immunogens delivered as a prime-boost regimen or coadministered in HIV-uninfected adults in the USA (HVTN 124): a phase 1, placebo-controlled, double-blind randomised controlled trial.

Ian Frank et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.